Actinogen Medical
Innovative neurotherapeutics developer advancing treatments for cognitive impairments and neurological disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 7.8x EV/Revenue -6.4x EV/EBITDA | round | |
| N/A | €0.0 | round | |
* | N/A | $8.9m | Post IPO Equity |
| Total Funding | 000k | ||
| AUD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (20 %) | - | - | 25 % | 104 % | 8 % | 55 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (122 %) | - | (227 %) | (207 %) | (123 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (133 %) | - | (237 %) | (215 %) | (128 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 138 % | - | 205 % | 178 % | 152 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for neurological diseases associated with dysregulated brain cortisol.
Actinogen Medical’s lead compound, Xanamem®, has been specifically designed to reduce production of intracellular cortisol - the stress hormone - through the inhibition of the 11β-HSD1 enzyme in the brain. The 11β-HSD1 enzyme is highly concentrated in the areas of the brain associated with cognitive decline in Alzheimer’s disease, potentially linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in other diseases. Because of its ability to reach these areas of the brain and inhibit this enzyme, Xanamem is very different from other treatments for cognitive impairment.
There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain affecting memory, cognitive function, behaviour and neuropsychological symptoms.
Actinogen’s clinical programme to date has demonstrated the safety and tolerability of Xanamem once daily in more than 200 healthy elderly volunteers and patients with Alzheimer’s disease. A statistically significant improvement was observed on computerised cognition testing. These results, along with other data recently generated, confirm 11β-HSD1 inhibition by Xanamem as a promising potential treatment for cognitive impairment.
The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2021. The XanaMIA study is planned to be conducted in two parts and is designed to study improvements in cognitive ability in older volunteers, and in patients with Mild Cognitive Impairment (MCI) due to Alzheimer’s disease. The XanaFX study studying male patients aged 12 to 18 will assess Xanamem’s effects on cognition, anxiety, sleep and behavioural problems.